For earnings season overall, consensus sees YoY earnings growth of just over 1%, marking the second straight quarter of earnings growth – and firmly marking the end of the 2023 earnings recession – if delivered. Revenue, meanwhile, is seen rising around 3% YoY during the quarter, marking the 12th consecutive quarterly increase.
As mentioned, banks kick off earnings season this week, with BofA, Citi, JPMorgan and Wells Fargo reporting before the open, followed by Goldman Sachs and Morgan Stanley early next week.
There will be several areas under the microscope with bank earnings, besides top- and bottom-line figures. Credit quality will be of particular interest, as the lagged impacts of the Fed’s tightening cycle continue to be felt, even if the macro conversation has moved on to when, and by how much, the FOMC are likely to ease policy this year. The amount of such non-performing loans is set to have risen sharply in the fourth quarter which, coupled with the ongoing dealmaking slump, and one-time charges being taken due to FDIC fees related to the collapse of Silicon Valley Bank (and others) last year, poses a downside risk to earnings in the fourth quarter.
CEO commentary around the aforementioned tightening cycle will also be of particular interest, not only in terms of the outlook that is foreseen over the course of the year ahead, but also the degree of deposit flight (largely into money market funds) seen as a result of the 500bp of hikes that the Fed delivered, as well as how net interest margins (NIMs) are likely to evolve as and when the FOMC begin to ease policy.
The financials sector more broadly has experienced a relatively average last 12 months, with the S&P 500 financials index having gained just shy of 8% over that period. Unsurprisingly, given the regional banking blowup last March, the banks sub-index has fared marginally worse, with the KBW Bank Index having somewhat recovered from the intra-year lows, albeit having thus far failed to reclaim the highs seen just prior to the aforementioned issues becoming evident, and the Fed’s BTFP scheme being unveiled.
Elsewhere in terms of earnings season, there are a few other stories worth watching. At broad level, Dow traders – owing to the price-weighted nature of the index – would be well-served by paying particular focus to earnings from UnitedHealth (UNH – 12th Jan), Goldman Sachs (GS – 16th Jan), Microsoft (MSFT – late-Jan), Home Depot (HD – late-Feb), and Amgen (AMGN – late-Jan), with those stocks being the top 5 weighted in the index, accounting for around a third of the index in total, with UNH alone holding a near-10% weight.
Of course, reports from the so-called ‘Magnificent Seven’ will also be in focus, not least owing to the remarkably strong performance exhibited by these stocks last year, and vastly outperformed the remaining 493 constituents in the S&P 500.
While many on the sell-side have been pointing to the likelihood that 2024 marks a year where value and small caps outperform, compared to their mega-cap counterparts, the opposite scenario appears more likely to pan out if, as most expect, economic momentum wanes as the year progresses.
Long Nasdaq/short Russell is a potential spread trade through which to express such a view, though earnings from the ‘big tech’ names aren’t due until late-January/early-February.
此处提供的材料并未按照旨在促进投资研究独立性的法律要求进行准备,因此被视为营销沟通。虽然它并不受到在投资研究传播之前进行交易的任何禁令,但我们不会在向客户提供信息之前谋求任何优势。
Pepperstone并不保证此处提供的材料准确、及时或完整,因此不应依赖于此。无论是来自第三方还是其他来源的信息,都不应被视为建议;或者购买或出售的要约;或是购买或出售任何证券、金融产品或工具的征求;或是参与任何特定交易策略。它并未考虑读者的财务状况或投资目标。我们建议此内容的读者寻求自己的建议。未经Pepperstone批准,不得复制或重新分发此信息。